Table 1.
Baseline characteristics of study participants (n = 762)
| Characteristicsa | Participants T1D (n = 423) |
Participants T2D (n = 339) |
|---|---|---|
| Sex (F/M), % (n) | 49/51 (206/217) | 29/71 (100/239) |
| Age, years | 53 (41–64) | 65 (58–71) |
| BMI, kg/m2 | 24.9 (22.6–27.6) | 29.2 (26.5–33.3) |
| Insulin pump, % (n) | 28.6 (121) | 0 (0) |
| Years with diabetes, y | 26 (14–39) | 15 (9–22) |
| Smokers, % (n) | 14 (58) | 12 (39) |
| HbA1c, mmol/mol/ % | 58 (52–65) / 7.5(6.9–8.1) | 57 (51–66) / 7.3 (6.8–8.1) |
| Blood cholesterol levels | ||
| Total cholesterol, mmol/l | 4.5 (4.0–5.1) | 4.0 (3.5–4.7) |
| HDL C, mmol/l | 1.55 (1.30–1.94) | 1.07 (0.89–1.30) |
| LDL C, mmol/l | 2.5 (2.0–2.9) | 2.0 (1.5–2.4) |
| Systolic blood pressure, mm Hg | 128 (120–136) | 130 (122–139) |
| Diastolic blood pressure, mm Hg | 76 (70–82) | 77 (71–82) |
| Medical treatment (%) | ||
| Insulin, % (n) | 100 (422) | 66 (225) |
| GLP-1a, % (n) | < 1 (1) | 30 (102) |
| OAD, % (n) | < 2 (6) | 81 (275) |
| OAD + insulin, % (n) | < 2 (6) | 47 (160) |
| Lipid lowering medication (statins), % (n) | 47 (200) | 85 (287) |
| Anti-hypertensive medication, % (n) | 56 (238) | 92(313) |
BMI body mass index, D-BP diastolic blood pressure, F female, GLP-1a glucagon-like peptide 1 analogues, HbA1c glycated haemoglobin A1c, HDL cholesterol, high-density lipoprotein cholesterol, LDL cholesterol, low-density lipoprotein cholesterol, OAD oral antidiabetic drugs, S-BP systolic blood pressure, T1D type 1 diabetes, T2D type 2 diabetes
aValues are either presented as median (IQRs) or number (n) and percentages (%) of study population